1. Celgene merger
2. Allergan merger
3. Buy Kite Pharma, Tesaro, Clovis Oncology, and Exelixis
2. Allergan merger
3. Buy Kite Pharma, Tesaro, Clovis Oncology, and Exelixis
-
Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page
Amgen acquisition targets that BD is now looking at...
- Thread starter anonymous
- Start date
-
- Tags
- None
You saw that Amgen is looking to buy and it's not buying the lakers
Follow number three above: Build an oncology pipeline by strategic acquisition of Exelixis for Cabu. Ignyta for entrectinib and their early and interesting molecules and targeted approach (a far better prospect than Tularik was in 2004). Tesaro for the PARP inhibitor. Kite etc...
Then enable these companies to develop their assets. Finally, integrate the best of the best from these companies to rebuild Amgen R+D. Time for some innovative risk takers in R+D and not yes men (looking at you Sean Harper and your team).
Igntya requires Amgen also to be smart and strong in companion diagnostics which it is not. The TO talent is not smart enough to gain this competency. Amgen is not attractive as a company to build that talent and current amgen employees would be jealous of those who came with that skillset. It would be like the jealous obu who hated onyx people because they were more talented and accomplished.
Amgen can barely market a therapeutic drug and they suck at it in oncology. Adding a diagnostic that they need to market and commercialize will be too hard for all the dumb people this company hires.
Lots of money to spend!!![/QUOTE
Didn't ex-CFO Peacock leverage all the overseas cash as backing for the corporate bonds. Whst happens to Amgens debt load if it is backed by aquisition assets rather than king cash? You guys are already on the high side of debt /equity in this industry.
Did not ex-CFO Peacock leverage the overseas cash already as backing for corporate bonds?.
The strategy created immediate liquidity, but left Amgen with higher debt /equity ratios than pharma industry peers. .How will Amgen's debt load be seen if backed by new acquisition assets rather than king cash?
Just trying to read if Amgen is a good investment or not.
Amgen needs to show growth or the stock price drops. High debt ratio is not ideal but lack of growth kills you. The question is whether goes for a mega-merger or a string of several large bolt on acquisitions.
With the cerebral Adema issue that shut down juno's lead program and now hit Kite Pharma, Amgen may be looking at the mega merger as the number of bolt on will be less and very competitive.
Appreciate you input. A merger would be more interesting. Bolt on aquisitions have not been very succeful
The amount of revenue growth Amgen needs exceeds what one emerging bolt on acquisition can provide it. Amgen needs revenue that can bring in 1.5 to 3 billion near term so that would be at least 2 if not 3 companies. The easiest thing would be a merger with Allergan, AZ, Celgene, etc.
The office of the future was not made for collaboration. It was for near term cost cutting and to tell sell property that would make Amgen easy to integrate.